1.Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev. 2008;40:553-624.
2.Chen WD, Zhang Y. Regulation of aldo-keto reductases in human diseases. Front Pharmacol. 2012;3:35.
3.Penning TM. The aldo-keto reductases (AKRs): Overview. Chem Biol Interact. 2015;234:236-46.
4.Huang L, He R, Luo W, et al. Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment. Recent Pat Anticancer Drug Discov. 2016;11:184-96.
5.Fang CY, Lin YH, Chen CL. Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients. J Oral Pathol Med. 2019;48:712-19.
6.Hung JJ, Yeh YC, Hsu WH. Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma. Thorac Cancer. 2018;9:1492-9.
7.Ko HH, Cheng SL. Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma. Head Neck. 2017;39:1327-32.
8.Ha SY, Song DH, Lee JJ, et al. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma. Gut Liver. 2014;8:648-54.
9.Schmitz KJ, Sotiropoulos GC, Baba HA, et al. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases. Liver Int. 2011;31:810-16.
10.Sonohara F, Inokawa Y, Hishida M, et al. Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue. Oncol Lett. 2016;12:4821-8.
11.Jin J, Liao W, Yao W, et al. Aldo-keto Reductase Family 1 Member B 10 Mediates Liver Cancer Cell Proliferation through Sphingosine-1-Phosphate. Sci Rep. 2016;6:22746.
12.Ahmed SMU, Jiang ZN, Zheng ZH, et al. AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy. Oncol Lett. 2019;17:773-80.
13.Liu TA, Jan YJ, Ko BS, et al. Regulation of aldo-keto-reductase family 1 B10 by 14-3-3epsilon and their prognostic impact of hepatocellular carcinoma. Oncotarget. 2015;6:38967-82.
14.Wang YY, Qi LN, Zhong JH, et al. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma. Sci Rep. 2017;7:42199.
15.Yao HB, Xu Y, Chen LG, et al. AKR1B10, a good prognostic indicator in gastric cancer. Eur J Surg Oncol. 2014;40:318-324.
16.Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-5.
17.Tierney JF, Stewart LA, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
18.Jumper N, Hodgkinson T, Arscott G, et al The Aldo-Keto Reductase AKR1B10 Is Up-Regulated in Keloid Epidermis, Implicating Retinoic Acid Pathway Dysregulation in the Pathogenesis of Keloid Disease. J Invest Dermatol. 2016;136:1500-12.
19.Ohashi T, Idogawa M, Sasaki Y, et al. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis. Mol Cancer Res. 2013;11:1554-63.
20.Zhou Z, Zhao Y, Gu L,et al. Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10. Mol Med Rep. 2018;17:2153-60.
21.Huang C, Verhulst S, Shen Y, et al. AKR1B10 promotes breast cancer metastasis through integrin alpha5/delta-catenin mediated FAK/Src/Rac1 signaling pathway. Oncotarget. 2016;7:43779-91.
22.Li J, Guo Y, Duan L, et al. AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling. Oncotarget. 2017;8:33694-703.
23.Wang C, Yan R, Luo D,et al. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem. 2009;284:26742-8.
24.Zhang W, Li H, Yang Y, et al. Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway. Cancer Lett. 2014;355:273-80.
25.Pyne NJ, Tonelli F, Lim KG,et al. Sphingosine 1-phosphate signalling in cancer. Biochem Soc Trans. 2012;40:94-100.
26.Liu Z, Yan R, Al-Salman A, et al. Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells. Biochem J. 2012;442:273-82.